Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Immunitas Therapeutics
Entity

Immunitas Therapeutics

Tracked across 1 events · 6 articles · First seen May 12, 2026 · Last active May 13, 2026

Sentiment
80
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 80
Business
Boehringer Ingelheim licenses Immunitas antibody program
Boehringer Ingelheim and Immunitas Therapeutics announced a global licensing agreement for a preclinical antibody program targeting chronic inflammatory and autoimmune diseases. Under the terms, Boehringer Ingelheim gains worldwide rights to develop, manufacture, and commercialize the…
Impact: Immunitas Therapeutics licensed its preclinical antibody program to Boehringer Ingelheim, receiving an upfront payment and eligibility for milestone payments up to €407.5 million, plus royalties, which will help advance its novel therapeutic into clinical development.
May 12, 2026 · 6 articles
Key Actions (2)
100 Immunitas Therapeutics received upfront payment Boehringer IngelheimBoehringer Ingelheim...
100 Boehringer Ingelheim obtained worldwide rights Immunitas TherapeuticsBoehringer Ingelheim...
NEWSDESK
Track Immunitas Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.